Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions

Patient safeguarding during high-dose psilocybin treatment is presented as a central ethical and clinical priority because the drug commonly produces intense alterations in cognition, perception, affect, and suggestibility that can be therapeutic but also distressing or destabilising. Earlier research and contemporary trials indicate that psychoeducation, preparation, and psychological support are important to promote safety and allow participants to derive therapeutic benefit. However, the field lacks standardised, manualised approaches to psychological support, which complicates comparisons across studies and raises regulatory concerns about consistent delivery and minimising bias in trials of investigational medicinal products. Kirlic and colleagues set out to describe the Compass Psychological Support Model (CPSM), a manualised framework developed to support participants receiving COMP360, Compass Pathfinder Ltd’s proprietary synthetic psilocybin formulation, within Compass-sponsored clinical trials. The paper explains the CPSM’s principles and three-stage structure (preparation, administration, integration), and outlines the therapist selection, training, mentoring, and fidelity-assessment procedures devised to ensure consistent, high-quality delivery in the Phase 3 multicentre, randomised, controlled, double-blind programme for treatment-resistant depression across Europe and North America.

The CPSM is delivered by licensed mental health professionals with relevant training or experience and is explicitly designed to accompany investigational COMP360 psilocybin administration rather than to function as a standalone psychotherapy. The intervention is structured across three stages: preparation (psychoeducation, expectation-setting, development of support strategies), administration (therapist presence with minimal intervention, safeguarding and use of agreed support strategies), and integration (participant-led reflection and consolidation while monitoring for persistent risk states). Psychoeducation is provided both through preparatory materials on a dedicated platform and in therapist sessions. Materials cover psilocybin’s putative mechanism of action, subjective effects, safety profile, the procedural flow of sessions, and practical skills (for example breath and body-awareness exercises) that participants practise in preparation. Therapists review participants’ understanding, clarify misconceptions, and co-create a plan for support strategies to be used during administration. The psychological-support component is organised around three key principles: trust and psychological safety, present-moment focus, and self-direction and autonomy. Trust is established by exploring personal history, trauma, cultural factors, and current mental-state to foster empathy and confidence in the therapeutic team. Present-moment focus is practised via open-ended inquiry about moment-to-moment experience and exercises to reduce experiential avoidance, which the authors link to worse outcomes in psychedelic sessions. Self-direction is emphasised to protect participants from undue suggestibility; therapists are trained to avoid giving advice, interpreting experiences, or steering outcomes, while helping participants set and revisit intentions for the session. Methods of support are individualised and rehearsed in preparation. Agreed strategies include experiential practices, proximity adjustments (therapist sitting closer without physical contact), pre-consented simple touch limited to non-sexual contact to arm or shoulder when explicitly agreed, and brief verbal cues. Therapists are trained to distinguish manageable emotional processing from intolerable distress and to implement support strategies sequentially. In rare extreme cases, psychiatrist evaluation and rescue medication (for example benzodiazepines or antipsychotics) may be used; the authors note that such interventions were uncommon in prior trials (<1.5% of participants receiving 25 mg). To ensure fidelity across sites, the CPSM is manualised and therapists undergo a multicomponent training programme including online self-study, review of prior-session recordings, experiential role-play, group discussion, competency benchmarking, ongoing group consultation with Compass-trained mentors, and independent fidelity ratings by expert raters to avoid unblinding. The phase 3 fidelity-assessment results were not available at the time of writing.

The authors conclude that the CPSM was designed to provide a baseline standard of psychological support for participants in COMP360 psilocybin clinical trials that both safeguards participant welfare and aligns with regulatory expectations for clearly specified, consistently delivered non-drug components of an investigational treatment. They emphasise that the CPSM is compatible with many evidence-based psychotherapeutic approaches but is not intended to be a standalone treatment for treatment-resistant depression or other psychiatric disorders. Finally, the authors call for future research to identify which elements of psychological support or adjunctive psychotherapy most effectively complement psilocybin, with a view to improving, personalising, and widening access to care.